ADVERSE EFFECTS OF HYDROXYUREA IN β-THALASSEMIA INTERMEDIA PATIENTS: 10 Years’ Experience

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pediatric Hematology & Oncology

• Publication date

  2010-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/08880011003639952PMID 20367264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Echocardiographic finding in beta‐thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta‐thalassemia intermedia

  2009cited by this paper
• Modern treatment of thalassaemia intermedia

  2007cited by this paper
• Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran

  2005cited by this paper
• Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

  2004cited by this paper
• Cutaneous Adverse Reactions to Hydroxyurea in Patients with Intermediate Thalassemia

  2004cited by this paper
• Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

  2003cited by this paper
• Rediscovering hydroxyurea: its role in recalcitrant psoriasis

  2001cited by this paper
• Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.

  2001cited by this paper
• Long‐Term Safety and Antiretroviral Activity of Hydroxyurea and Didanosine in HIV‐Infected Patients

  2000cited by this paper
• Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera.

  2000cited by this paper
• Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial

  2000cited by this paper
• [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].

  1999cited by this paper
• Preliminary report of a toxicity study of hydroxyurea in sickle cell disease

  1999cited by this paper
• Hydroxyurea Therapy in Thalassemia a

  1998cited by this paper
• Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

  1998cited by this paper
• Increase in Hemoglobin Concentration during Therapy with Hydroxyurea in Cooley's Anemia

  1998cited by this paper
• Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.

  1997cited by this paper
• Successful use of hydroxyurea in beta-thalassemia major.

  1997cited by this paper
• Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis

  1995cited by this paper
• Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.

  1995cited by this paper
• Pharmacologic treatment of thalassemia intermedia with hydroxyurea.

  1994cited by this paper
• Beta-thalassemia syndromes and pregnancy.

  1994cited by this paper
• Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

  1984cited by this paper
• THALASSEMIA INTERMEDIA; GENETIC AND BIOCHEMICAL CONSIDERATIONS.

  1964cited by this paper
• Thalassemia Intermedia: Genetic and Biochemical Considerations

  1964cited by this paper
• Comparison of Sixty‐Six Patients With Thalassemia Major and Thirteen Patients with Thalassemia Intermedia: Including Evaluations of Growth, Development, Maturation and Prognosis *

  1964cited by this paper

• Screening and treatment of thalassemia.

  2025cites this paper
• Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis

  2025cites this paper
• Impact of Hydroxyurea to Treat Haematological Disorders on Male Fertility: Two Case Reports and a Systematic Review

  2024cites this paper
• Thalassemia Disorders: A Scoping Insight toward Management and Patient Care Prospects

  2024cites this paper
• Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.

  2023cites this paper
• Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience

  2021cites this paper
• Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease

  2020cites this paper
• Association of Exon 14 of the SOX6 Gene Sequence Variations with Response to Hydroxyurea Therapy in Patients Carrying Non Transfusion-Dependent Thalassemia

  2020cites this paper
• Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening

  2020cites this paper
• Anemia in the Young and Old

  2019cites this paper
• Thiourea derivatives induce fetal hemoglobin production in-vitro: A new class of potential therapeutic agents for β-thalassemia.

  2019cites this paper
• Anemia at the Extremes of Life: Congenital Hemolytic Anemia

  2018cites this paper
• β-Thalassemia intermedia: a comprehensive overview and novel approaches

  2018cites this paper
• Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction

  2018cites this paper
• Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With &bgr;-Thalassemia Intermedia

  2017cites this paper
• Metallomic profiling to evaluate the response to drug treatment: hydroxyurea as a case study in β-thalassemia patients

  2017cites this paper
• Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

  2016cites this paper
• Pharmacogenomics for Haemoglobinopathies Therapeutics

  2015cites this paper
• Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports

  2015cites this paper
• First Report of Acute Lymphoblastic Leukemia in an Egyptian Child with β-Thalassemia Major

  2015cites this paper
• α:Non-α and Gγ:Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea.

  2014cites this paper
• Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

  2014cites this paper
• Guidelines for Diagnosis and Management of Beta-Thalassemia Intermedia

  2014cites this paper
• Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013

  2014cites this paper
• Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in Egypt

  2014cites this paper
• Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

  2014cites this paper
• Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia

  2014cites this paper
• Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients

  2014cites this paper
• Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea

  2014cites this paper
• Effect of Hydroxy Urea in treatment of patients with thalassemia Intermedia

  2014cites this paper
• The Effect and Side Effect of Hydroxyurea Therapy on Patients With β-Thalassemia: A Systematic Review to December 2012

  2014cites this paper
• Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.

  2013influential citation
• Induction of HBF

  2013cites this paper
• b -Thalassemia Intermedia: A Clinical Perspective

  2012influential citation
• Contemporary approaches to treatment of beta-thalassemia intermedia.

  2012cites this paper
• Indywidualizowane postępowanie terapeutyczne związane z płucnymi powikłaniami leczenia hydroksymocznikiem u 43-letniego mężczyzny z nadpłytkowością samoistną Individualized therapy as a consequence of the hydroxyurea pulmonary toxicity in a 43-year-old man with essential thrombocythemia

  2012cites this paper
• β-thalassemia intermedia: a clinical perspective.

  2012cites this paper
• Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B

  2011cites this paper
• Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran

  2011cites this paper
• Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

  2010cites this paper